

Press Release

Resistant to coronaviruses: Semperit protective glove brings professional safety to Austrian households

- High-quality protective glove from Austria available in retail stores for the first time
- Market launch with BIPA in early September
- Production at the only European production facility for surgical gloves in Wimpassing, Lower Austria

Vienna/Austria, 2 September 2020 – The protective gloves of the Austrian Semperit Group, which have been tried and tested by medical personnel, will also ensure professional safety in Austrian households in the future: from the beginning of September 2020, Semperit's protective glove, which is resistant to coronaviruses among other things, will be available in household sizes for end users at the Austrian drugstore chain BIPA.

“The massive demand for protective equipment in the context of CoViD-19 can often only be fulfilled by foreign manufacturers who do not always meet EU standards. In order to counteract this problem and the associated quality deficiencies, we have decided to also produce protective gloves for end users at our domestic headquarters in Wimpassing. After supplying more than 60 million examination and protective gloves for medical personnel at the beginning of the corona crisis, we are pleased that we can now also contribute to improved individual protection during the pandemic in Austria with Semperit's protective glove for end consumers,” says Martin Füllenbach, Chairman of the Executive Board of Semperit AG Holding.

The glove production in Wimpassing is the only production facility for surgical gloves in Europe. In the future, Austrian households will also benefit from the strong focus on quality that is necessary to meet the high demands in the medical sector. The Semperit protective glove is produced from a renewable raw material; the glove material is resistant to bacteria, fungi and viruses, including SARS-CoV-2, hepatitis B&C and HIV. Semperit protective gloves will be available in about 600 BIPA stores throughout Austria, and in the BIPA online shop at www.bipa.at.

Contact

Monika Riedel
Director Group Brand Management,
Corporate Spokesperson
+43 676 8715 8620
monika.riedel@semperitgroup.com
www.semperitgroup.com

Judit Helenyi
Director Investor Relations
+43 676 8715 8310
judit.helenyi@semperitgroup.com

About Semperit

The publicly listed company Semperit AG Holding is an internationally-oriented group that develops, produces, and sells in more than 100 countries highly specialised rubber products for the industrial and medical sectors: hydraulic and industrial hoses, conveyor belts, escalator handrails, construction profiles, cable car rings, products for railway superstructures and examination and surgical gloves. The headquarters of this long-standing Austrian company, which was founded in 1824, are located in Vienna. The Semperit Group employs around 7,000 people worldwide, including about 3,800 in Asia

and around 900 in Austria (Vienna and production site in Wimpassing, Lower Austria). The Group has 14 manufacturing facilities worldwide and numerous sales offices in Europe, Asia, Australia, and America. In 2019, the group generated revenue of EUR 840.6 million and an adjusted EBITDA (without one-off effects) of EUR 63.8 million.

About Sempermed

Sempermed is the medical segment of the Semperit Group and ranks among the internationally leading manufacturers of medical and industrial gloves. In Wimpassing, Lower Austria, home of the research centre and the production facility for surgical gloves, new products are continually developed, tested and produced in close cooperation with users and experts. For 100 years, Sempermed has been producing gloves of the highest quality and setting standards in terms of innovation. Sempermed guarantees optimum safety and reliability through modern manufacturing technologies, highest production hygiene and strictest quality controls. In January 2020, Semperit took the fundamental strategic decision to concentrate on the industrial rubber business in the future and divest the glove division. The implementation of this fundamental strategic decision was delayed due to the corona crisis.